LMWH Regimen for Left Ventricular Apical Thrombus
For left ventricular apical thrombus, use enoxaparin 1 mg/kg subcutaneously every 12 hours or dalteparin 200 units/kg once daily for at least 3 months, with consideration for longer duration if risk factors persist. 1, 2
Recommended LMWH Dosing Regimens
Enoxaparin:
- 1 mg/kg subcutaneously every 12 hours 3
- Alternative: 1.5 mg/kg once daily (though twice-daily dosing is preferred for therapeutic anticoagulation) 3
Dalteparin:
- 200 units/kg subcutaneously once daily 3
- This is the full therapeutic dose for venous thromboembolism treatment 3
Treatment Duration and Monitoring
Minimum treatment duration is 3 months, with strong consideration for extended or indefinite anticoagulation based on:
- Persistent LV dysfunction or reduced ejection fraction 2, 4
- Ongoing apical akinesis or dyskinesis 4
- Presence of dilated cardiomyopathy 1, 2
- Active malignancy (if applicable) 3
Baseline laboratory testing should include: CBC, renal and hepatic function panel, aPTT, and PT/INR 3
Follow-up monitoring:
- Hemoglobin, hematocrit, and platelet count every 2-3 days for the first 14 days, then every 2 weeks thereafter 3
- Serial echocardiography (bi-weekly initially) to assess thrombus resolution 1
Important Considerations and Caveats
Renal function is critical:
- If creatinine clearance <30 mL/min, use caution with LMWH due to accumulation risk 3
- Consider unfractionated heparin (UFH) IV with aPTT monitoring (80 units/kg bolus, then 18 units/kg/hour) in severe renal impairment 3
Concomitant antiplatelet therapy:
- If patient is post-MI and requires dual antiplatelet therapy, this creates "triple therapy" with increased bleeding risk 5, 2, 4
- Bleeding risk increases significantly (OR 2.85) but must be balanced against thromboembolic risk 5
- The 2022 American Heart Association Scientific Statement acknowledges this complexity but supports anticoagulation for LVT despite bleeding concerns 2
Evidence quality note:
- While VTE guidelines are robust, LVT-specific data is more limited 2
- The single prospective study of LMWH for LVT (enoxaparin 100 IU/kg twice daily) showed 73% thrombus resolution with no major bleeding in 26 patients 1
- Current practice extrapolates heavily from VTE treatment protocols 3
Transition considerations:
- If transitioning to warfarin, overlap LMWH for minimum 5 days until INR is therapeutic (2.0-3.0) for at least 24 hours 3
- Direct oral anticoagulants (DOACs) are increasingly used as alternatives, though warfarin remains the traditional standard 2, 4
Common pitfall: Stopping anticoagulation immediately after thrombus resolution—embolic events can occur even after LVT disappears, suggesting need for extended therapy in high-risk patients 4